Literature DB >> 12697089

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

Jory R Baldridge1, Christopher W Cluff, Jay T Evans, Michael J Lacy, Jeffrey R Stephens, Valerie G Brookshire, Rong Wang, Jon R Ward, Yvonne M Yorgensen, David H Persing, David A Johnson.   

Abstract

Earlier we showed that the structural requirements for adjuvanticity among the aminoalkyl glucosaminide 4-phosphate (AGP) class of synthetic immunostimulants may be less strict than those for other endotoxic activities, including the induction of nitric oxide synthase in murine macrophages and cytokine production in human whole blood. The known role of nitric oxide and pro-inflammatory cytokines in the activation of host defenses against infection prompted us to examine the ability of certain AGPs to enhance non-specific resistance in mice to Listeria monocytogenes and influenza infections as well as to stimulate the production of pro-inflammatory cytokines in mouse splenocytes, human PBMCs, and human U937 histiocytic lymphoma cells. Intranasal administration of RC-524 or RC-529 to mice 2 days prior to a lethal influenza challenge provided significant protection in each case. Similarly, the intravenous administration of these AGPs induced resistance to L. monocytogenes infection as measured by survival or reduction of bacteria in the spleen. Activation of the innate immune response by AGPs appears to involve activation of Toll-like receptor 4 (TLR4) because RC-524 failed to elicit a protective effect in C3H/HeJ mice which have a defect in TLR4 signaling or induce significant cytokine levels in C3H/HeJ splenocytes. Both AGPs also stimulated pro-inflammatory cytokine release in human cell cultures in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12697089     DOI: 10.1179/096805102125001064

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  15 in total

1.  Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.

Authors:  Ida Rosenkrands; Else Marie Agger; Anja W Olsen; Karen S Korsholm; Claire Swetman Andersen; Klaus T Jensen; Peter Andersen
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

3.  Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.

Authors:  Naoki Okamoto; Keisuke Mizote; Hiroe Honda; Akinori Saeki; Yasuharu Watanabe; Tomomi Yamaguchi-Miyamoto; Ryutaro Fukui; Natsuko Tanimura; Yuji Motoi; Sachiko Akashi-Takamura; Tatsuhisa Kato; Shigeto Fujishita; Takahito Kimura; Umeharu Ohto; Toshiyuki Shimizu; Takatsugu Hirokawa; Kensuke Miyake; Koichi Fukase; Yukari Fujimoto; Yoshinori Nagai; Kiyoshi Takatsu
Journal:  J Biol Chem       Date:  2017-07-28       Impact factor: 5.157

Review 4.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

5.  PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.

Authors:  Bruce A Green; Ying Zhang; Amy W Masi; Vicki Barniak; Michael Wetherell; Robert P Smith; Molakala S Reddy; Duzhang Zhu
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Authors:  Christopher W Cluff; Jory R Baldridge; Axel G Stöver; Jay T Evans; David A Johnson; Michael J Lacy; Valerie G Clawson; Vonnie M Yorgensen; Craig L Johnson; Mark T Livesay; Robert M Hershberg; David H Persing
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 7.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

Review 8.  The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.

Authors:  Julia K Bohannon; Antonio Hernandez; Perenlei Enkhbaatar; William L Adams; Edward R Sherwood
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

Review 9.  A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.

Authors:  Jinhee Hyun; Saravana Kanagavelu; Masayuki Fukata
Journal:  Microbes Infect       Date:  2012-10-29       Impact factor: 2.700

10.  Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.

Authors:  Asher Maroof; Yvonne M Yorgensen; Yufeng Li; Jay T Evans
Journal:  PLoS Pathog       Date:  2014-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.